…the Street isn't too happy about what Mylan is paying for Meda.
The 92% premium is high, but Meda is an excellent fit for MYL, especially in emerging markets (#msg-120456955).
Some investors have evidently succumbed to the flawed logic promulgated by Bernstein’s Ronny Gal: that MYL could have accomplished much more for shareholders by applying the $9.9M deal value entirely to share buybacks. The logic flaw in this notion is that MYL would be badly over-leveraged if it increased net debt by $9.9B without any corresponding increase in operating cash flow to service that debt.
News 
Market Data 
Discover 
